Psoriasis drug: FDA approves Siliq for moderate-to-severe plaque psoriasis
by Press Release from Outbreak News Today on (#2CWGH)
The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and ["]
The post Psoriasis drug: FDA approves Siliq for moderate-to-severe plaque psoriasis appeared first on Outbreak News Today.